Reuters reported that Heineken's October advice to British pubs raised the possibility that glucagon-like peptide-1 (GLP-1) medicines could reduce alcohol orders, a concern for a UK beer market that recently set a sales record.
In a presentation Reuters said Heineken sent to hospitality customers, the brewer linked the medicines to appetite-related fullness and fewer drink orders. It recommended that venues consider half-pints, low- and no-alcohol options, and small plates, while warning that pub visits and customer spending could decline.
Heineken UK's 2026 Beer Report put beer sales at pubs, bars and restaurants at £14 billion for the data period ending Feb. 21, 2026, up 5% from a year earlier. The report, citing CGA by NIQ OPM data, put no- and low-alcohol beer sales at £271 million, a 31% increase. It also described a shift toward lower beer volumes per visit and more spending on premium choices; 55% of surveyed beer drinkers said they would pay extra for better-quality beer.
A February 2026 online survey by Drinkaware and KAM asked 207 current or former GLP-1 users about their drinking. Respondents reported drinking an average of 2.2 days a week after starting medication, down from 3.1 days before, and consuming 3.6 alcohol units per week, compared with 4.3 beforehand. Those answers reflect self-reported behavior, not pub sales.
Clinical evidence comes from a different population. In a 26-week Lancet trial, 108 people with obesity seeking treatment for moderate-to-severe alcohol use disorder received semaglutide or a placebo alongside cognitive behavioral therapy; 88 completed the intervention. Heavy-drinking days fell from baseline by 41.1 percentage points in the semaglutide group and 26.4 percentage points in the placebo group, with an estimated treatment difference of 13.7 percentage points. The study did not measure pub demand.
Carlsberg told Reuters that available data did not yet show GLP-1 medicines to be a clear driver of beer-consumption trends. Heineken said it had observed changes among users and would continue monitoring their behavior in 2027.
